Why the study?
Does radiation therapy improve overall survival in adult patients with primary mediastinal large B-cell lymphoma in the rituximab era?
Does radiation therapy improve overall survival in adult patients with primary mediastinal large B-cell lymphoma in the rituximab era?
Radiation therapy did not significantly improve overall survival in patients with primary mediastinal large B-cell lymphoma in the rituximab era, suggesting it may be safely omitted in select patients to avoid cardiopulmonary toxicities.
No takes yet. Share an insight, caveat, or question.
RT omission may be considered in rituximab-era PMBCL; leaves open need for prospective trials to confirm equivalence.
Giri et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: